Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06658353
Recruiting Phase 3

Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors

NCT06658353 · tracked via the Priya Life Science China tracker
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Phase
Phase 3
Started
2025-03-17
Last updated
2026-07-27

Condition(s) studied

Locally Advanced Solid Tumor

Investigational drug(s) / intervention(s)

VC004 Capsules →

VC004 Capsules: VC004 Capsules BID

Study summary

This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.

Eligibility

Sex
ALL
Min age
12 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures； * Male or female, age ≥12 years old; Exclusion Criteria: * Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures); * Adverse reactions caused by previous treatment have not recovered to ≤1 grade (evaluated by the investigator); * Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug.

Primary outcome measure(s)

  • Objective response rate(ORR) — 6 months

Trial sites (1)

FacilityCityRegionStatus
Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College Beijing Beijing Municipality Recruiting

More Jiangsu vcare pharmaceutical technology co., LTD trials in China

Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis Recruiting
Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. Recruiting
Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects Starting soon
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo Recruiting
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis Recruiting

Other trials for the same condition

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors Recruiting
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06658353 on ClinicalTrials.gov ↗ ← All trials in China